vs
CRISPR Therapeutics AG（CRSP）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是CRISPR Therapeutics AG的2.0倍（$71.1M vs $35.7M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -104.5%，领先106.6%），RE/MAX Holdings, Inc.同比增速更快（-1.8% vs -82.3%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-50.3M）
CRISPR Therapeutics AG是一家瑞美合资生物技术企业，总部位于瑞士楚格，在美国以CRISPR Therapeutics, Inc.名义开展业务。作为首批依托CRISPR基因编辑平台开发药物的企业之一，公司现有约500名员工，在瑞士楚格、美国波士顿、旧金山及英国伦敦设有办公点，专注于多种罕见病与常见病的治疗药物研发。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
CRSP vs RMAX — 直观对比
营收规模更大
RMAX
是对方的2.0倍
$35.7M
营收增速更快
RMAX
高出80.4%
-82.3%
净利率更高
RMAX
高出106.6%
-104.5%
自由现金流更多
RMAX
多$83.8M
$-50.3M
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.7M | $71.1M |
| 净利润 | $-37.3M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -181.0% | 13.1% |
| 净利率 | -104.5% | 2.0% |
| 营收同比 | -82.3% | -1.8% |
| 净利润同比 | -141.8% | -75.2% |
| 每股收益（稀释后） | $-0.41 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRSPRMAX
| Q4 25 | — | $71.1M | ||
| Q3 25 | — | $73.2M | ||
| Q2 25 | — | $72.8M | ||
| Q1 25 | — | $74.5M | ||
| Q4 24 | $35.7M | $72.5M | ||
| Q3 24 | — | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
净利润CRSPRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | $-37.3M | $5.8M | ||
| Q3 24 | — | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
营业利润率CRSPRMAX
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | 19.3% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | -181.0% | 5.9% | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
净利率CRSPRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | -104.5% | 8.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
每股收益（稀释后）CRSPRMAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-0.41 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9B | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $1.9B | $452.4M |
| 总资产 | $2.2B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资CRSPRMAX
| Q4 25 | — | $118.7M | ||
| Q3 25 | — | $107.5M | ||
| Q2 25 | — | $94.3M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | $1.9B | $96.6M | ||
| Q3 24 | — | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
总债务CRSPRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益CRSPRMAX
| Q4 25 | — | $452.4M | ||
| Q3 25 | — | $448.1M | ||
| Q2 25 | — | $442.4M | ||
| Q1 25 | — | $433.5M | ||
| Q4 24 | $1.9B | $429.5M | ||
| Q3 24 | — | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
总资产CRSPRMAX
| Q4 25 | — | $582.5M | ||
| Q3 25 | — | $582.2M | ||
| Q2 25 | — | $574.8M | ||
| Q1 25 | — | $571.4M | ||
| Q4 24 | $2.2B | $581.6M | ||
| Q3 24 | — | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
负债/权益比CRSPRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.0M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-50.3M | $33.5M |
| 自由现金流率自由现金流/营收 | -140.9% | 47.1% |
| 资本支出强度资本支出/营收 | 0.7% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-325.9M | $56.8M |
8季度趋势，按日历期对齐
经营现金流CRSPRMAX
| Q4 25 | — | $40.9M | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.7M | ||
| Q4 24 | $-50.0M | $59.7M | ||
| Q3 24 | — | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
自由现金流CRSPRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | $-50.3M | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率CRSPRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | -140.9% | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度CRSPRMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 0.7% | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率CRSPRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRSP
| Collaboration Revenue | $35.0M | 98% |
| Grant | $2.3M | 6% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
